STOCK TITAN
  1. Home
  2. News
  3. TCRX

TScan Therapeutics, Inc. - TCRX STOCK NEWS

Welcome to our dedicated page for TScan Therapeutics news (Ticker: TCRX), a resource for investors and traders seeking the latest updates and insights on TScan Therapeutics stock.

TScan Therapeutics, Inc. (NASDAQ: TCRX) is a pioneering biopharmaceutical company focused on developing advanced T-cell receptor (TCR) engineered T cell therapies (TCR-T) aimed at treating cancer. Specializing in harnessing novel T cell systems, TScan is at the forefront of extending the promise of immunotherapy to patients with hematologic malignancies and solid tumors.

The company's leading therapies, TSC-100 and TSC-101, are designed to eliminate residual leukemia and prevent relapse in patients with blood cancers such as acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) undergoing hematopoietic stem cell transplantation. These liquid tumor TCR-T therapy candidates are currently in development, reflecting TScan's commitment to improving patient outcomes.

TScan is also developing multiplexed TCR-T therapy candidates for treating various solid tumors, showcasing the company's versatility and innovative approach in the immunotherapy landscape. Recent recognition includes the RMAT designation granted for both TSC-100 and TSC-101, highlighting their potential significance in cancer treatment.

In addition to its groundbreaking therapeutic developments, TScan Therapeutics maintains strong partnerships and a robust financial foundation. The company frequently updates its stakeholders through transparent communication and investor relations, ensuring that all relevant developments and milestones are promptly shared.

For the latest news and updates, you can contact Heather Savelle, VP of Investor Relations, at 857-399-9840 or via email at hsavelle@tscan.com. Further inquiries can also be directed to Joyce Allaire, Managing Director at LifeSci Advisors, LLC, at 617-435-6602 or jallaire@lifesciadvisors.com.

News

TScan Therapeutics Announces Upcoming Presentations at the 2024 American Society of Clinical Oncology Annual Meeting

Rhea-AI Summary
TScan Therapeutics, Inc. (Nasdaq: TCRX) is set to present two abstracts at the 2024 American Society of Clinical Oncology Annual Meeting. The presentations focus on T cell receptor-engineered T cell therapies for cancer treatment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.22%
Tags
conferences
-
News

TScan Therapeutics Announces Exercise of Underwriters' Option to Purchase Additional Shares

Rhea-AI Summary
TScan Therapeutics announced the partial exercise of underwriters' option to purchase additional shares, resulting in gross proceeds of approximately $167.8 million from a total of 4,958,068 shares sold at $7.13 per share. The underwriters of the public offering closed on April 19, 2024, have partially exercised their over-allotment option, leading to the purchase of 2,485,487 additional shares of voting common stock. Morgan Stanley and TD Cowen served as joint book-running managers for the offering.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.65%
Tags
none
-
News

TScan Therapeutics Announces Upcoming Presentations at the American Society of Gene and Cell Therapy 27th Annual Meeting

Rhea-AI Summary
TScan Therapeutics, Inc. (Nasdaq: TCRX) will present at the ASGCT 27th Annual Meeting with one oral and four poster presentations focusing on TCR-engineered T cell therapies for cancer treatment. The company aims to showcase advancements in tumor-reactive TCRs and T cell therapies for various cancers, emphasizing non-clinical and clinical trial progress.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.97%
Tags
conferences
News

TScan Therapeutics Announces Closing of Upsized Public Offering

Rhea-AI Summary
TScan Therapeutics, Inc. (Nasdaq: TCRX) closed an underwritten public offering of 2,472,581 shares of its common stock and pre-funded warrants for approximately $150.1 million. The company granted underwriters an option to purchase additional shares. The proceeds will be used for general corporate purposes, extending the company's cash runway into the fourth quarter of 2026.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.45%
Tags
offering
-
News

TScan Therapeutics Announces Pricing of Upsized $150 Million Public Offering

Rhea-AI Summary
TScan Therapeutics, a biopharmaceutical company, announced the pricing of an upsized $150 million public offering. The offering includes shares of its voting common stock and pre-funded warrants, with gross proceeds expected to be approximately $150.1 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.33%
Tags
offering
-
News

TScan Therapeutics Announces Launch of $125 Million Proposed Public Offering

Rhea-AI Summary
TScan Therapeutics, a biopharmaceutical company, is launching a $125 million public offering for the development of TCR-T cell therapies for cancer treatment. The offering includes voting common stock and pre-funded warrants, with underwriters having an option to purchase additional shares. The proceeds will be used for general corporate purposes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.33%
Tags
offering
News

TScan Therapeutics Provides Clinical Pipeline Update and Highlights Near-Term Priorities

Rhea-AI Summary
TScan Therapeutics, Inc. (Nasdaq: TCRX) provides an update on its solid tumor and heme malignancies clinical programs. Over 40 solid tumor patients completed biomarker testing, with 60% qualifying for TCR-T therapy. All heme program patients remain relapse-free. The company plans to dose the first three solid tumor patients in early May 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.33%
Tags
none
-
News

TScan Therapeutics Appoints Seasoned Hematology and Oncology Expert Chrystal U. Louis, M.D., M.P.H., as Chief Medical Officer

Rhea-AI Summary
TScan Therapeutics appoints Dr. Chrystal Louis as Chief Medical Officer, bringing extensive experience in hematology and oncology drug development. Dr. Louis will lead the clinical and commercial development of TCR-engineered T cell therapies for cancer treatment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.53%
Tags
management
-
News

TScan Therapeutics Announces Upcoming Presentation at the 23rd Annual Needham Virtual Healthcare Conference

Rhea-AI Summary
TScan Therapeutics, Inc. (TCRX) will present at the 23rd Annual Needham Virtual Healthcare Conference to discuss their TCR-engineered T cell therapies for cancer treatment. The presentation will be available via webcast on their website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.11%
Tags
conferences
News

TScan Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Rhea-AI Summary
TScan Therapeutics, Inc. (TCRX) reports updated data from Phase 1 study showing positive outcomes for heme malignancies treatment. They also announced the clearance of two additional INDs for their Solid Tumor Program. Financially, the company has strong cash reserves to fund operations into 2026 and has seen revenue growth in 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.71%
Tags
earnings

FAQ

What is the current stock price of TScan Therapeutics (TCRX)?

The current stock price of TScan Therapeutics (TCRX) is $4.26 as of November 22, 2024.

What is the market cap of TScan Therapeutics (TCRX)?

The market cap of TScan Therapeutics (TCRX) is approximately 225.8M.

What is TScan Therapeutics, Inc.?

TScan Therapeutics, Inc. is a biopharmaceutical company specializing in T-cell receptor (TCR) engineered T cell therapies (TCR-T) for cancer treatment.

What are TScan's leading therapy candidates?

TScan's leading therapy candidates are TSC-100 and TSC-101, aimed at treating blood cancers like AML and ALL.

What recent recognition has TScan's therapies received?

TSC-100 and TSC-101 have been granted RMAT designation for their potential in treating AML, ALL, and MDS.

What types of cancer does TScan focus on?

TScan focuses on hematologic malignancies and various solid tumors.

How does TScan aim to improve cancer treatment?

TScan aims to improve cancer treatment by developing TCR-T therapies that target and eliminate residual cancer cells, reducing the risk of relapse.

How can I contact TScan's Investor Relations?

You can contact Heather Savelle, VP of Investor Relations, at 857-399-9840 or via email at hsavelle@tscan.com.

Where can I get the latest updates about TScan?

Latest updates and news can be found by contacting TScan's Investor Relations or visiting their official website.

What is the stock symbol for TScan Therapeutics, Inc.?

TScan Therapeutics, Inc. trades on NASDAQ under the symbol TCRX.

Who are the key contacts for media inquiries at TScan?

For media inquiries, you can contact Heather Savelle at TScan Therapeutics or Maghan Meyers at Argot Partners.

What are TScan's goals in immunotherapy?

TScan aims to extend the promise of immunotherapy through innovative TCR-T cell therapies that offer new hope to cancer patients.

Stock TCRX logo
TScan Therapeutics, Inc.

Nasdaq:TCRX

TCRX Rankings

#3769 Ranked by Market Cap
N/A Ranked by Dividends

TCRX Stock Data

225.76M
52.81M
0.88%
99.33%
4.09%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States of America
WALTHAM